title: Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
abstract: OBJECTIVE
  To evaluate the proportion of patients with type 2 diabetes mellitus (T2DM) achieving reductions in both glycated hemoglobin (HbA1c) and body weight with canagliflozin, a sodium glucose co-transporter 2 inhibitor, versus sitagliptin over 52 weeks.
  
  
  METHODS
  Data were pooled from two, randomized, Phase 3 studies of canagliflozin 100 and 300 mg versus sitagliptin 100 mg as add-on to metformin, and canagliflozin 300 mg versus sitagliptin 100 mg as add-on to metformin plus sulfonylurea (N = 1856). The composite end points of change from baseline in both HbA1c <0% and body weight <0 kg, and attainment of HbA1c <7.0% and body weight reduction ≥5% at Week 52 were evaluated. Safety was assessed based on adverse event reports.
  
  
  RESULTS
  Canagliflozin provided reductions in HbA1c and body weight over 52 weeks versus sitagliptin. A greater proportion of patients had both HbA1c and body weight reductions with canagliflozin 100 and 300 mg versus sitagliptin 100 mg (67.7%, 72.6%, and 44.1%, respectively). Among patients with HbA1c and body weight reductions, more patients achieved the composite end point of HbA1c <7.0% and body weight reduction ≥5% with canagliflozin 100 and 300 mg versus sitagliptin 100 mg (18.9%, 18.3%, and 5.7%, respectively). Canagliflozin was generally well tolerated.
  
  
  CONCLUSIONS
  A greater proportion of patients with T2DM achieved reductions in both HbA1c and body weight, and more patients with HbA1c and body weight reductions achieved HbA1c <7.0% and body weight reduction ≥5% with canagliflozin versus sitagliptin over 52 weeks.
  
  
  BACKGROUND
  www.ClinicalTrials.gov identifiers are NCT01106677; NCT01137812.
authors.affiliation: a Department of Medicine , Rudolfstiftung Hospital-Vienna , Vienna , Austria.
authors.forename: Guntram
authors.initials: G
authors.lastname: Schernthaner
authors.affiliation: b Endocrinology and Internal Medicine Department , Universidad Autonoma de Nuevo Leon , Monterrey , Mexico.
authors.forename: Fernando J
authors.initials: FJ
authors.lastname: Lavalle-González
authors.affiliation: c Touchstone Diabetes Center , The University of Texas Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Jaime A
authors.initials: JA
authors.lastname: Davidson
authors.affiliation: d Metabolic Disease Associates , Erie , PA , USA.
authors.forename: Holly
authors.initials: H
authors.lastname: Jodon
authors.affiliation: e Janssen Research & Development, LLC , Raritan , NJ , USA.
authors.forename: Ujjwala
authors.initials: U
authors.lastname: Vijapurkar
authors.affiliation: e Janssen Research & Development, LLC , Raritan , NJ , USA.
authors.forename: Rong
authors.initials: R
authors.lastname: Qiu
authors.affiliation: e Janssen Research & Development, LLC , Raritan , NJ , USA.
authors.forename: William
authors.initials: W
authors.lastname: Canovatchel
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D001835:Body Weight; D000068896:Canagliflozin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D044469:Racial Groups; D000068900:Sitagliptin Phosphate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D015431:Weight Loss / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000068896:Canagliflozin; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008687:Metformin; D000068900:Sitagliptin Phosphate; D013453:Sulfonylurea Compounds
keywords: Canagliflozin; antihyperglycemic agent; body weight; sodium glucose co-transporter 2 (SGLT2) inhibitor; type 2 diabetes mellitus